Selected adverse events during the 12-week induction period of a phase III trial of vunakizumab: an exploratory post-hoc analysis
ObjectiveThis study aimed to investigate the impact of vunakizumab on adverse events (AEs) in patients with moderate-to-severe plaque psoriasis.MethodsThis exploratory post-hoc analysis used data from a phase III trial (NCT04839016). A total of 690 pat…